Surgery to remove the mesorectum is the standard of care for patients with locally advanced rectal cancer ([@bib16]). In locally advanced disease, when neoadjuvant chemoradiotherapy (CRT) is combined with radical surgery, very low rates of local recurrence are reported ([@bib33]; [@bib42]; [@bib4]). However, radical surgery combined with neoadjuvant therapy is associated with considerable perioperative morbidity with many patients experiencing diminished quality of life owing to bladder/sexual dysfunction, low anterior resection syndrome in addition to the potential for a permanent stoma ([@bib20]; [@bib27]; [@bib38]; [@bib17]).

The ultimate goal of organ preservation is to deliver equivalent oncological outcomes with reduced surgical risk and improved functional outcome leading to 'better\' quality of life. Previously only used for palliative purposes and in the local treatment of early (T1) rectal cancer, organ (rectum)-preservation strategies have been proposed as a curative approach for more advanced rectal cancer, where an objective response to neoadjuvant CRT has been observed ([@bib19]; [@bib23]; [@bib35]; [@bib43]; [@bib10]). Complete response (no residual tumour) to treatment is seen in 10--30% of patients in whom active surveillance or local excision may be a viable option ([@bib2]; [@bib24]; [@bib40]). Increasing the interval to assessment beyond 6--8 weeks following the completion of neoadjuvant treatment, radiotherapy boost via external-beam or contact therapy, and induction/consolidation chemotherapy are strategies that may increase complete response rates ([@bib41]; [@bib11]; [@bib8]; [@bib36]; [@bib9]).

Implementation of organ-preservation strategies has been hindered by the inability to accurately define a complete clinical response using imaging modalities. A complete endoluminal response on sigmoidoscopy is suggestive of complete pathological response, however, neither magnetic resonance imaging (MRI) or positron emission tomography (PET)--computed tomography (CT) are sufficiently sensitive at current resolutions to be definitive ([@bib26]; [@bib37]; [@bib14]). Mucosal biopsies of a scar or residual ulcer may also not be definitive, owing to tumour scatter and submucosal persistence resulting in false-negative results ([@bib12]; [@bib15]; [@bib28]; [@bib7]). Patients downstaged to ypT0 or ypT1 have a low risk of positive lymph nodes (\<5%), however, tumours staged ypT2 carry a risk of positive nodes closer to 20%, thus a decision concerning definitive surgery must incorporate methods to stratify patients according to ypT stage. One option is to perform transanal excision of any residual scar or ulcer (excision biopsy) to establish the ypT stage ([@bib38]; [@bib24]). The results presented here represent an observational study of organ-preservation strategies in patients with locally advanced rectal cancer found to have objective endoluminal response to neoadjuvant CRT.

Materials and methods
=====================

Study design and participants
-----------------------------

Institutional ethical approval was granted for the prospective accrual and follow-up of patients with adenocarcinoma of the rectum (\<15 cm from the anal verge) ([Figure 1](#fig1){ref-type="fig"}). All patients underwent full colonoscopy and complete staging with digital rectal exam, serum carcinoembryonic antigen, CT of thorax, abdomen and pelvis (CT--TAP), MRI of the pelvis and PET--CT if indicated. Endoscopic ultrasound was used to differentiate T1 from T2 tumours that could not be adequately staged by MRI. Patients were discussed at a multidisciplinary team meeting (MDT) and categorised into receiving neoadjuvant CRT, or to proceed directly to surgical excision with total mesorectal excision. Locally advanced rectal cancer was defined as tumours ⩾T3 or any T stage with nodal involvement evident on MRI imaging, defined as both short-axis dimension \>5 mm and abnormal morphological features.

Procedures
----------

Patients received standard long-course CRT (50--54 Gy for 5 weeks with 5-fluorouracil). After a 6--8 weeks interval, they underwent clinical, endoscopic and radiological (CT thorax and abdomen, and MRI pelvis) restaging and MDT review. Patients with complete endoluminal response to treatment (visible scar only) or a residual scar/ulcer ⩽3 cm in diameter were defined as having an objective clinical response if this correlated with radiological downstaging in the absence of distant disease. Written informed consent was obtained from all patients who were fully appraised of the treatment options including standard surgery with total mesorectal excision. Patients with a complete endoluminal response to therapy were offered an active surveillance programme ('watch and wait\'). In the case of objective endoluminal response but residual ulcer, transanal excision was offered and performed 10--12 weeks after completion of neoadjuvant CRT. This was performed via transanal excision, transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS) under general anaesthetic. A 1 cm macroscopic margin was considered desirable. A predetermined strategy was salvage total mesorectal excision for ⩾ypT2 tumours or those with positive margins. Local regrowth was treated with salvage surgery. Adjuvant chemotherapy was given to patients who were clinically node-positive prior to neoadjuvant CRT.

Resected specimens were examined by two consultant pathologists. Tumour staging was performed using the TNM classification and response to therapy was assessed using a three-point tumour regression grade system (TRG 1--3; [@bib32]). Clinical follow-up was at 6 weeks and 3--6 monthly intervals thereafter including endoscopic assessment. All patients had six monthly CT--TAP scans (for 3 years), whereas organ-preserved patients had MRI pelvis every 3--6 months. A tumour regrowth was defined as a luminal recurrence at the site of the original tumour, whereas a local recurrence was defined as extra luminal tumour regrowth.

Outcomes
--------

The primary study end points were overall and disease-free survival. Secondary end points were complete pathological response rates and local regrowth/recurrence rates.

Statistics
----------

Continuous data are presented as medians with interquartile ranges (IQRs) or means if normally distributed (s.d.). Overall and disease-free survival was calculated using Kaplan--Meier analysis with a 95% confidence interval and log-rank test. Statistical analysis was performed using IBM SPSS Statistics (version 20, Armonk, NY, USA).

Results
=======

A total of 785 patients were treated for rectal cancer (2005--2015), of whom 362 patients with non-metastatic, locally advanced rectal cancer were treated with neoadjuvant CRT ([Figure 1](#fig1){ref-type="fig"}). Sixty out of three hundred and sixty-two (16.5%) patients had an objective clinical response and chose to be treated by an organ-preservation approach. The remaining 302 patients with persistent endoluminal tumour underwent total mesorectal excision, of whom 48 (15.9%) were subsequently found to have a complete pathological response ([Table 1](#tbl1){ref-type="table"}).

Ten patients with complete endoluminal response were treated with a 'watch and wait\' (active surveillance) approach. Fifty patients with an objective endoluminal response underwent local excision at 10--12 weeks post CRT. Twenty-eight patients (56%) were treated with transanal excision, 16 (32%) had TEMs, whereas 6 (12%) had TAMIS. Fifteen patients had ⩾ypT2 tumours or margins \<1 cm post local excision and were subsequently treated with total mesorectal excision. Forty-five patients were maintained in an organ-preservation programme, 10 in active surveillance (cT0 tumours) and 35 in local excision group (26 ypT0, 4 ypT1 and 5 patients with ypT2 tumours who declined radical surgery/stoma).

After a median follow-up of 29 months (IQR 12--49) for the local excision group (*n*=35), overall survival was 94.3%. One death occurred in the ypT0 cohort owing to respiratory sepsis, while one patient staged ypT1 died of disease progression ([Table 2](#tbl2){ref-type="table"}). Disease-free survival was 80%, five patients developed a distant recurrence after a median of 20 months (range 5--45) and 3 patients developed tumour regrowth (2 ypT0) after a median of 21 months (range 17--31). One patient, staged ypT2, developed both distant recurrence and local regrowth ([Table 2](#tbl2){ref-type="table"}). All tumour regrowths were treated with salvage total mesorectal excision (two abdominoperineal resections) achieving negative resection margins with no post-operative mortality.

Ten patients underwent active surveillance ('watch and wait\') with a median follow-up of 42 months (IQR 22.5--55.2 months). Disease-free survival was 80%. Tumour regrowth occurred in one patient at 19 months that was treated with total mesorectal excision achieving clear margins. One distant recurrence occurred at 50 months with one death occurring owing to disease progression at 51 months.

Fifteen patients were referred directly for radical surgery post local excision owing to adverse pathological findings (⩾ypT2 tumours or positive margins). Pathological assessment of resected specimens showed 2 ypT0 tumours, 10 ypT2 tumours and 3 ypT3 tumours. Nodal positivity occurred in four patients with negative resection margins achieved in all (five abdominoperineal resections). One death occurred owing to respiratory sepsis after a median of 70 months follow-up, whereas disease progression accounted for the other death after 16 months. Overall survival was 86.7% ([Table 2](#tbl2){ref-type="table"}). Adjuvant chemotherapy was given to 39 out of 60 patients treated initially with organ preservation, 23 ypT0, 2 ypT1, 11 ypT2 and 3 ypT3.

After a median follow-up of 45 months (range 5--120 months), overall survival was 85.6% in the radical resection group with disease-free survival of 78.3%. There was no significant difference in overall survival (85.6% *vs* 93.3%, *P*=0.414) or disease-free survival rate (78.3% *vs* 80%, *P*=0.846) when the outcomes of radical surgery were compared with organ preservation (active surveillance and local excision, *n*=45; [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Discussion
==========

Proctectomy with total mesorectal excision is the standard of care for locally advanced rectal cancer ([@bib16]). In locally advanced disease, when neoadjuvant CRT is combined with radical surgery, very low rates of local recurrence are reported ([@bib33]; [@bib42]; [@bib4]). The present study shows that organ-preservation techniques are suitable for selected patients with locally advanced rectal cancer in whom an objective clinical response is found after neoadjuvant therapy. This approach can achieve equivalent oncological outcomes by means of either active surveillance ('watch and wait\') or local excision followed by active surveillance.

The multicentre ACOSOG Z6041 trial evaluated organ preservation for T2N0 distal rectal tumours treated with neoadjuvant CRT and local excision. High toxicity rates were encountered when oxaliplatin was included, however, long-term results were impressive with 3-year overall survival of 94.8% and excellent local recurrence rates of 4% ([@bib10]). Functional outcomes and quality of life were assessed in this trial, with a return to normal bowel function and good quality of life observed 1 year after surgery ([@bib10]). Radical surgery combined with neoadjuvant therapy is associated with considerable perioperative morbidity with many patients experiencing diminished quality of life owing to bladder/sexual dysfunction, low anterior resection syndrome in addition to the potential for a permanent stoma ([@bib20]; [@bib27]). The purpose of organ preservation is to achieve similar oncological outcomes to those of radical surgery while maintaining quality of life and functional ability ([@bib1]; [@bib10]; [@bib31]).

[@bib23] randomised patients with T2N0M0 distal rectal cancers \<3 cm in diameter to receive neoadjuvant CRT followed by local excision or radical surgery. The local recurrence rates in the local excision group were 8% compared with 6% in the radical resection group after 5 years of follow-up. Similar recurrence rates were seen in the present study, even with inclusion of patients with more locally advanced (\>T3) tumours. A meta-analysis of local excision post neoadjuvant therapy *vs* radical surgery showed that local recurrences were not significantly greater (10.1% local excision *vs* 8% radical resection), and there was no difference in overall or disease-free survival, even in T3 and node-positive patients ([@bib35]).The Dutch CARTS trial assessed organ sparing surgery by TEM for patients clinically staged with distal T1-3N0 cancers. They achieved organ-preservation surgery in 55% of patients. Complete pathological rates were seen in \>30% with no local recurrences occurring in this group ([@bib43]).

Organ-preservation strategies are dependent on tumour regression following neoadjuvant CRT. Complete response is seen in 10--30% of patients undergoing neoadjuvant CRT ([@bib24]; [@bib37]). Short-course radiotherapy has been shown to achieve similar oncological outcomes when compared with long course, however, without a delay to surgery, pathological downstaging is more frequently seen with long-course therapy ([@bib42]; [@bib44]; [@bib30]). Increasing the interval to surgery \>8 weeks following neoadjuvant therapy may improve response rates ([@bib18]; [@bib36]; [@bib29]). This has been questioned recently, as the Greccar 6 trial showed little benefit (on complete response rates) if the interval to surgery was longer than 7 weeks ([@bib21]). Some centres have omitted radiotherapy from their regimes, with complete response rates of 25% being reported with chemotherapy alone ([@bib34]). However, when contact or external-beam radiotherapy are used, better local control and pathological outcomes are seen ([@bib41]; [@bib11]).

Adjuvant chemotherapy is used to improve overall and disease-free survival in node-positive patients, although the true benefit of adjuvant chemotherapy after neoadjuvant CRT has been questioned ([@bib5]). Giving systemic chemotherapy in the neoadjuvant setting (induction/consolidation chemotherapy) has the added benefit of managing micrometastasis earlier, while delivering treatment to well-vascularised tissues and improving compliance rates. Increased pathological responses are seen when this technique has been used, making it an attractive approach for patients entered into an organ-preservation approach ([@bib8]; [@bib6]; [@bib9]).

One pitfall to implementing an organ-preservation approach is the difficulty in accurately defining a complete clinical response. Local excision allows full-thickness assessment of the tumour site and accurate ypT staging, an advantage over a 'watch and wait\' approach. Full-thickness excision may lead to better local control compared with a non-operative approach, however, this was not assessed here. This must be balanced against the potential morbidity of local excision in a radiated operative field ([@bib25]; [@bib13]).

Patients in the present study who were found not to have an objective clinical response underwent timely radical surgery. Total mesorectal excision allows accurate lymph-node staging, something organ-preservation strategies do not. Patients with ypT0-1 have a lymph-node positivity rate of ∼3% (range 1--10), but this increases to \>20% with ypT2 tumours and \>33% with ypT3 tumours ([@bib38]; [@bib24]). Therefore, total mesorectal excision should be considered for ⩾ypT2 tumours.

Recurrence rates in patients treated with local excision of rectal cancer can be high. Depth of tumour invasion, presence of lymphovascular or perineural invasion, poor differentiation or positive margins, all contribute to increased risk of local recurrence. In the present study, all local recurrences and locally excised tumours found to have adverse pathological features were treated with salvage total mesorectal excision, however, anatomical distortion post local excision can lead to more challenging resections with higher rates of positive margins and abdominoperineal resections reported ([@bib22]; [@bib25]).

There are a number of limitations to this study. It is a single-centre experience with a relatively small sample size and short follow-up. No randomisation occurred that could have contributed to selection bias. However, this centre is participating in the international watch and wait programme, a registry incorporating multiple worldwide institutes, which will further help to validate this approach ([@bib3]).

In conclusion, this study shows that this organ-preservation strategy can achieve equivalent oncological outcomes in selected patients with locally advanced rectal cancer achieving an objective response to neoadjuvant CRT.
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![**Kaplan--Meier estimates of overall survival for patients maintained by organ-preservation techniques (*n*=45) *vs* total mesorectal excision (*n*=302), *P*=0.414.**](bjc2016417f2){#fig2}

![**Kaplan--Meier estimates of disease-free survival for patients maintained by organ-preservation techniques (*n*=45) *vs* total mesorectal excision (*n*=302), *P*=0.846.**](bjc2016417f3){#fig3}

###### Patient characteristics

  **Patient characteristics**                   **Radical surgery (*n*=302)**      **Organ preservation (*n*=60)**
  -------------------------------------------- ------------------------------- ----------------------------------------
  Median age (range)                                     64 (27--90)                         67 (46--87)
  Gender                                                                                           
   Male: female                                       189 : 113 (3 : 1)                    45 : 15 (2 : 1)
  Clinical T stage (%)                                                                             
   T1                                                         0                                2 (3.3%)
   T2                                                     36 (12%)                            20 (33.3%)
   T3                                                     230 (76%)                           38 (63.4%)
   T4                                                     36 (12%)                                0
  Clinical nodal stage (%)                                                                         
   Positive                                              220 (72.8%)                          35 (58.3%)
   Negative                                              82 (27.2%)                           25 (41.7%)
  Pathological differentiation (%)                                                                 
   Well/moderate                                         271 (89.7%)                          60 (100%)
   Poor                                                  31 (10.3%)                               0
  Pathological T stage (%)                                                                         
   ypT0                                                  48 (15.9%)             26 (43.33%)[a](#t1-fn1){ref-type="fn"}
   ypT1                                                    21 (7%)                            4 (6.67%)
   ypT2                                                  72 (23.8%)                          17 (28.33%)
   ypT3                                                   136 (45%)                             3 (5%)
   ypT4                                                   25 (8.3%)                               0
  Pathological nodal stage (%)                                                                     
   ypN0                                                  198 (65.5%)                             ---
   ypN1/ypN2                                             104 (34.5%)                             ---
  Pathological tumour regression grade (TRG)                                                       
   TRG 1                                                 48 (15.9%)              26 (52%)[a](#t1-fn1){ref-type="fn"}
   TRG 2                                                 182 (60.3%)                           24 (48%)
   TRG 3                                                 72 (23.8%)                               0

Ten patients entered into watch and wait programme -- clinical complete responders.

###### Patient outcomes

                                **TME (*n*=302)**   **Watch and wait (*n*=10)**   **Local excision (*n*=35)**  **Salvage TME post local excision (*n*=15)**
  ---------------------------- ------------------- ----------------------------- ----------------------------- ----------------------------------------------
  Overall survival                    85.6%                     90%                          94.3%             86.6%
  Disease-free survival               78.2%                     80%                           80%              60%
  Tumour regrowth/recurrence           19                        1                             3               1
  Distant recurrence                   47                        1                             5               5

Abbreviation: TME=total mesorectal excision.
